/ FDA
/ Market Analysis
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals
Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.
December 01, 2025
Why Did Biohaven Stock Collapse in Premarket Today? FDA Rejects Its Lead Drug Vyglxia
Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease progression.
November 05, 2025
Why Did Outlook Therapeutics (OTLK) Shares Crash Today?
Outlook Therapeutics stock crashed 70% in premarket after the FDA rejected its wet AMD drug application, citing insufficient efficacy evidence despite previous trial successes.
August 28, 2025
Ars Pharmaceuticals Shares Hit All-Time Low as FDA Rejects EpiPen Alternative
Shares of drugmaker Ars Pharmaceuticals crashed over 57% after FDA disapproved its EpiPen alternative.
September 20, 2023
Push for Novel COVID-19 Treatment Leads to Stock Market Rally
How will the rally end?
August 24, 2020
Back to 
